Compounded hydroquinone: identify the approval record precisely

FDA says compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before marketing. The agency also explains circumstances in which compounding can meet a patient's medical need, such as an ingredient allergy or a need for a different dosage form. Those examples describe the framework, not evidence that a particular advertised formula is necessary for a reader. FDA's questions and answers provide that distinction.

An individualized rationale would come from the clinician considering an actual patient. The term customized on a public page cannot establish what was assessed, which alternative was considered or what the eventual prescription contains. Nor does nonapproval alone describe the outcome of every compounded preparation.

FDA's currently posted hydroquinone safety communication, dated April 19, 2022, says there are no FDA-approved or otherwise legally marketed OTC skin-lightening products and identifies TRI-LUMA as the only FDA-approved drug containing hydroquinone. It also discusses serious reported harms, including rashes, facial swelling and ochronosis. These are FDA's statements about the regulatory and safety context. The communication should not be shortened to a claim that every prescription hydroquinone cream is approved.

An online offer's use of prescription language does not establish its finished-product approval status. Conversely, this article does not use that announcement to issue a legal verdict on an individual compounded prescription. Those are separate questions requiring the actual product and applicable circumstances.

TRI-LUMA contains three specified active ingredients, including hydroquinone, within its labeled cream. Its indication concerns moderate to severe facial melasma, with specific limitations and sun-protection context. The inspected DailyMed record was updated October 24, 2024; its prescribing information is revised February 2023. Those dates describe the source version reviewed, not a claim about present retail stock. The exact label is the reference.

A different mixture cannot acquire that approval because it contains hydroquinone or also has three ingredients. The percentage-comparison guide shows why ingredient counts and strengths cannot replace product identity. The same discipline applies when a provider mentions evidence for a familiar ingredient alongside its own preparation.

CoreAge calls Spot On a compounded cream and names hydroquinone, kojic acid and niacinamide. That explicit description supports attributing compounding to the offer. It does not establish FDA approval of the mixture, its precise pharmacy identity or the complete formulation that would appear on a patient's prescription. CoreAge's product page is a provider record, not an FDA approval document.

The Spot On review preserves the separate advertised concentrations and unresolved base information. The Obagi record review is another exercise in exact naming: similar product-family names should not substitute for the specific record under discussion. Public descriptions are useful evidence, but their source and role need to stay visible.

An NDC entry can help identify a listed drug record. FDA expressly states that inclusion in the National Drug Code Directory does not mean it has approved the product, or verified the information provided to the agency. The FDA directory explanation prevents a common shortcut: treating a searchable identifier as an approval certificate.

A DailyMed record likewise needs its actual content read; the existence of a drug-information page is not, by itself, the approval argument. In this guide, the approval claim for TRI-LUMA is anchored to FDA's hydroquinone communication and the exact labeled medicine. A precise identifier is valuable for matching records, but it cannot answer a different regulatory question merely by looking official.

The patient-facing record should make it possible to discuss the prescribed formula, the dispensing pharmacy and questions about the product received. FDA notes that online consumers may not know the compounder and recommends discussing medicine questions with a health professional. Its compounding guidance is especially relevant when a brand name is more prominent than the preparation details.

The fixed preparation reader offers questions without authenticating a pharmacy or examining a package. The Dermatica record review applies the same distinction between public descriptions and a personal prescription. The follow-up guide considers another missing piece: which professional reviews changes after prescribing. A clearly advertised service does not prove that a particular handoff has occurred. Record matching and clinical review remain real tasks for the people responsible for care.

This publication serves the CoreAge Rx promotional network. Its first commercial position reflects that affiliation, which readers should consider when interpreting the provider comparison. The relationship supplies no clinical endorsement, exemption or evidence of regulatory clearance for an individual preparation.

The resulting reading habit is simple but specific: retain the complete product name whenever a source makes an approval statement, retain the provider's attribution whenever it describes a compound, and leave unanswered details visible. That approach allows an informed discussion without replacing either the professional assessment or the actual dispensing documentation with a website summary.